Sugi Predict

Sugi Predict / Compounds / SCHEMBL837547

SCHEMBL837547

SCHEMBL837547

CC(C)(C)OCc1ccc(C[C@H](N)C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 6/20 0.62
▸ PTGS1 P23219 3/20 0.56
▸ ALPI P09923 1/20 0.56
▸ PKM P14618 1/20 0.56
▸ XIAP P98170 1/20 0.56
▸ GRB2 P62993 1/20 0.53
▸ PTPN1 P18031 2/20 0.52
▸ TPH1 P17752 1/20 0.49
▸ HIF1A Q16665 4/20 0.49
▸ ALOX15 P16050 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ TDP1 Q9NUW8 2/20 0.49
▸ USP2 O75604 1/20 0.49
▸ EGFR P00533 1/20 0.49
▸ LCK P06239 1/20 0.49
▸ FYN P06241 1/20 0.49
▸ ADORA3 P0DMS8 1/20 0.49
▸ HTR2A P28223 1/20 0.49
▸ PTGS2 P35354 1/20 0.49
▸ RECQL P46063 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24846017 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1258517 0.83 SLC7A5 (0.75) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL6743907 0.83 SLC7A5 (0.75) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1258521 0.83 SLC7A5 (0.75) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL13660584 0.82 SLC7A5 (0.55) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL21002204 0.81 SLC7A5 (0.86) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL12142641 0.81 SLC7A5 (0.68) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL17655704 0.81 SLC7A5 (0.68) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL5222909 0.81 SLC7A5 (0.92) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL6374042 0.81 SLC7A5 (0.92) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9115169-B2 Method of treating tumors LYTIX BIOPHARMA AS (NO) 2015-08-25 — — US disclosed
US-9109048-B2 Inhibition of tumor growth LYTIX BIOPHARMA AS (NO) 2015-08-18 — — US disclosed
US-20140037657-A1 INHIBITION OF TUMOR GROWTH LYTIX BIOPHARMA AS (NO) 2014-02-06 — — US disclosed
US-8283315-B2 Inhibition of tumour growth LYTIX BIOPHARMA AS (NO) 2012-10-09 — — US disclosed
US-20120108520-A1 Antimicrobial Compounds and Formulations LYTIX BIOPHARMA AS (NO) 2012-05-03 — — US disclosed
US-8143211-B2 Bioactive peptides LYTIX BIOPHARMA AS (NO) 2012-03-27 — — US disclosed
US-8048852-B2 Antimicrobial compounds and formulations LYTIX BIOPHARMA AS (NO) 2011-11-01 — — US disclosed
EP-1263471-B1 ANTIMICROBIAL COMPOUNDS AND FORMULATIONS LYTIX BIOPHARMA AS (NO) 2011-10-12 — — EP disclosed
EP-2338522-A1 Antitumoural therapies Lytix Biopharma AS (NO) 2011-06-29 — — EP disclosed
US-20100267621-A1 Antimicrobial Compounds and Formulations LYTIX BIOPHARMA AS (NO) 2010-10-21 — — US disclosed
US-6890902-B2 Cytotoxic modified lactoferrin peptides ALPHARMA AS (NO) 2005-05-10 — — US disclosed
US-20030195144-A1 Antimicrobial compounds and formulations LYTIX BIOPHARMA AS (NO) 2003-10-16 — — US disclosed
US-20030148936-A1 Bioactive peptides ALPHARMA AS. 2003-08-07 — — US disclosed
US-20030022821-A1 Bioactive peptides ALPHARMA AS 2003-01-30 — — US disclosed
EP-1263471-A2 ANTIMICROBIAL COMPOUNDS AND FORMULATIONS ALPHARMA AS (NO) 2002-12-11 — — EP disclosed
WO-2001066147-A2 ANTIMICROBIAL COMPOUNDS AND FORMULATIONS ALPHARMA AS (NO) 2001-09-13 — — WO disclosed
EP-1109831-A2 CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2001-06-27 — — EP disclosed
EP-1109827-A2 BIOACTIVE PEPTIDES ALPHARMA AS (NO) 2001-06-27 — — EP disclosed
WO-2000012541-A2 CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 — — WO disclosed
WO-2000012542-A2 CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108520-A1 Antimicrobial Compounds and Formulations VIP, NONO, CLPTM1 SLC7A5 28/4885PTGS1 1996/4885ALPI 2661/4885
US-20100267621-A1 Antimicrobial Compounds and Formulations VIP, NONO, CLPTM1 SLC7A5 28/4885PTGS1 1996/4885ALPI 2661/4885
US-20030148936-A1 Bioactive peptides VIP, NGLY1, HM13 SLC7A5 79/4885PTGS1 3979/4885ALPI 3910/4885
US-20030195144-A1 Antimicrobial compounds and formulations LPO, CLPTM1, VIP SLC7A5 72/4885PTGS1 2103/4885ALPI 1907/4885
US-20030022821-A1 Bioactive peptides VIP, LITAF, LNPEP SLC7A5 111/4885PTGS1 3546/4885ALPI 712/4885
US-20140037657-A1 INHIBITION OF TUMOR GROWTH STING1, VIP, MIF SLC7A5 37/4885PTGS1 1091/4885ALPI 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.